Sanofi grabs a share of No­vavax's Covid vac­cine for $500M, eye­ing com­mer­cial­iza­tion, flu com­bi­na­tion

Sanofi is hand­ing No­vavax $500 mil­lion up­front to bring the biotech’s Covid-19 vac­cine in­to the fold, with dual goals of co-com­mer­cial­iz­ing the cur­rent vac­cine and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER